Medically reviewed by Jamin Brahmbhatt, MD The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves ...

On an ordinary day in Brighton, Dheeresh Turnbull swabbed the inside of his cheek for science. He was healthy, with no ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study. Here is a roundup of March 2025 U.S. FDA ...

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

Even among patients with prostate cancer liver metastasis who have a poor prognosis, elevated ctDNA fraction and tumor suppressor gene loss differentiate survival.

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors -- a smart fighter that destroys cancer cells for days without tiring. Biomedical engineers have made this ...

Artificial intelligence can help urologists and oncologists make treatment recommendations that are objective and evidence-based.

Researchers have unlocked a powerful new way to fight solid tumors using smart immune cells that stay active longer and hit ...